Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: cooksbay95 who wrote (1450)	11/18/1998 9:53:00 AM
From: Biomaven	Respond to of 10280

Felodipine is an Astra-Merck drug (Plendil). It's a calcium channel blocker, with moderate sales (around $100m). The patent claims reduced side effects, but the side effect profile of the original drug is already pretty good (some peripheral edema seems to be the most common side-effect), and so I'm not sure how significant this new patent is. Mostly it's significant because it shows that SEPR's window of opportunity for additional ICE drugs apparently isn't yet closed. Peter